Opus Genetics Inc expected to post a loss of 16 cents a share - Earnings Preview

Opus Genetics

07/08/2026 12:15

Opus Genetics Inc IRD.OQ IRD.O is expected to  show a fall in quarterly revenue when it reports  results  for the period ending September 30 2026
The Durham North Carolina-based  company is expected to report a 17.2% decrease in revenue to $2.55 million from $3.08 million a year ago, according to the mean estimate from 17 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Opus Genetics Inc is for a loss of 16 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had fallen by about 10.0% in the last three months. ​
Wall Street's median 12-month price target for Opus Genetics Inc is $10.00, about 168.8% above its last closing price of $3.72
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.15
-0.16
-0.14
Beat
10.7
Mar. 31 2026
-0.14
-0.14
-0.75
Missed
-426.3
Dec. 31 2025
-0.11
-0.12
-0.29
Missed
-149.2​
Sep. 30 2025
-0.13
-0.13
-0.25
Missed
-92.3
​​Jun. 30 2025
-0.21
-0.20
-0.12
Beat
41.5
Mar. 31 2025
-0.26
-0.25
-0.24
Beat
4​
Dec. 31 2024
-0.26
-0.22
Beat
14.3
Sep. 30 2024
-0.25
-0.24
-0.29
Missed
-22.1
This summary was machine generated August 7 at 11:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)